PanGenomic Health Announces Adoption of Semi-Annual Reporting

Vancouver, British Columbia, Canada, November 23, 2026 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA, FSE:LL3) announces that it is relying on the exemptions provided under Coordinated Blanket Order 51-933 – *Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers* (the "**Blanket Order**") and moves to semi-annual financial reporting ("**SAR**").

The Blanket Order allows eligible venture issuers to voluntarily move from quarterly to semi-annual financial reporting. By adopting SAR, the Company aims to reduce the administrative and financial burden associated with quarterly reporting.

Under the Blanket Order, the Company will be exempt from filing interim financial reports and related Management's Discussion and Analysis ("MD&A") for its first and third quarters. As a result, the Company will not file interim financial statements and related MD&A for the nine-month period ended September 30, 2026. The Company will continue to file audited financial statements and MD&A (due within 120 days of December 31) and six-month interim financial statements and MD&A (due within 60 days of June 30).

The Company confirms that it meets the Blanket Order's eligibility criteria, which include being a venture issuer with annual revenues of less than $10 million, having a disclosure record of over 12 months and having filed all required periodic and timely continuous disclosure documents.

This news release is being filed pursuant to Coordinated Blanket Order 51 – 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote alternative health solutions tailored to the health profile of each individual. To learn more about PanGenomic Health's products and services: www.pangenomic.com or email: info@pangenomic.com.

For more information, please contact:

Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 305 5369
fair@fairfax.partners

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe", "plans" and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca. Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

.